Inclacumab
Modify Date: 2024-04-11 11:09:48
Inclacumab structure
|
Common Name | Inclacumab | ||
|---|---|---|---|---|
| CAS Number | 1256258-86-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of InclacumabInclacumab (Anti-Human selectin P Recombinant Antibody) is a humanized monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 µg/mL and strongly inhibits cell adhesion[1][2][3]. |
| Name | Inclacumab |
|---|
| Description | Inclacumab (Anti-Human selectin P Recombinant Antibody) is a humanized monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 µg/mL and strongly inhibits cell adhesion[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Inclacumab (0.4-40 μg/mL; 5 min) significantly reduces flow adhesion of P-Selectin with Whole Blood (WB) and isolated White Blood Cell (I-WBC) and shows a more stronger effect on isolated white cells[1]. Inclacumab shows great binding affinity to P-selectin with a Kd value of 9.9 nM[2]. Inclacumab inhibits PSGL-1 mimetic peptide binding with P-selectin with an IC50 value of 1.9 µg/mL[2]. Inclacumab blocks the adhesion of PSGL-1 expressing cells to an immobilized P-selectin with an IC50 value of 430 ng/mL[2]. Inclacumab (0-100 μg/mL; 5min) dose-dependently inhibits thrombin receptor-activating peptide (TRAP)-induced platelet-leukocyte aggregates (PLA) levels with an IC50 value of 1.4 μg/mL[3]. |
| In Vivo | Inclacumab (4 mg/kg; s.c. once) reduces TRAP- and ADP-induced PLA levels in cynomolgus monkeys[3]. Inclacumab (2-50 mg/kg; i.v.; once a week for 13 weeks) inhibits TRAP induced PLA levels in cynomolgus monkeys[3]. Animal Model: Cynomolgus monkeys[3] Dosage: 4 mg/kg Administration: Subcutaneous injection; 4 mg/kg; once Result: Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs. Animal Model: Cynomolgus monkeys[3] Dosage: 2, 10, and 50 mg/kg Administration: Intravenous injection; once daily; for 13 weeks Result: Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period. |
| References |
| No Any Chemical & Physical Properties |